FLT3 and chronic myelogenous leukemia, BCR-ABL1 positive: Based on these results, we next asked whether dual inhibition of BCR::ABL1 and FLT3 could overcome TKI resistance in xenograft mouse models and eradicate patient-derived BP-CML cell growth.